Clinical study on the effects of naloxone nasal spray for the treatment of gambling disorder
- Conditions
- Problem gamblingMedDRA version: 20.0 Level: LLT Classification code 10017657 Term: Gambling pathological System Organ Class: 100000167845Therapeutic area: Psychiatry and Psychology [F] - Behaviours [F01]
- Registration Number
- EUCTR2017-001946-93-FI
- Lead Sponsor
- ational Instute of Health and Welfare
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 126
1.Aged 18 to 75 years, fluent in Finnish and able to read and understand the patient information sheet
2.Provide written, informed consent prior to any study specific procedure being conducted
3.Gambling problem at pre-screening (SOGS = 5)
4.Moderate (6-7 criteria met) or severe (8-9 criteria met) GD (DSM-5) assessed by clinical interview with Medical Doctor (MD)
5.At least 4 weeks since completion of any other previous treatment for GD
6.At least 8 weeks since completion of any previous treatment with naltrexone or nalmefene
7.Willingness to comply with all study procedures and visit schedules
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 126
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
1.Two weeks or longer abstinence from gambling prior to randomisation
2.Known allergic reactions to naloxone or excipients of IMP and placebo
3.Current use of drugs (opiates, amphetamine, metamphetamine, cocaine, cannabis and benzodiazepines) (as assessed by saliva drug screen, DrugWipe-6)
4.Subject is taking any prohibited medication (opioid analgesics, any medication delivered to the nose)
5.Serious mental illness or severe Depression assessed by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Disorders (SCID-I, DSM-5) and the Montgomery and Asberg Depression Rating Scale (MADRS) scores =24
6.Clinically significant risk of suicide (Columbia-Suicide Severity Rating Scale (C-SSRC))
7.Women who are pregnant or breastfeeding at screening or Baseline
8.Serious kidney (P-Creatinine > 110 umol/ml) insufficiency
9.The Subject/patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
10.Liver cirrhosis or liver enzyme elevations, ASAT or ALAT >200 (by blood drop test),
11.Active HCV infection (saliva test, OralQuick-HCV)
12.The person that met the criteria of vulnerable person according to Finnish Medical Research Act No188/1999 7-10§
13.Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless surgically sterile must use effective contraception (either combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD], intrauterine hormone-releasing system [IUS], vasectomised partner, sexual abstinence (only considered an acceptable method of contraception when it is in line with the subjects’ usual and preferred lifestyle), combination of male condom with either cap, diaphragm or sponge with spermicide [double barrier methods]), and willing and able to continue contraception for 1 month after the last administration of IMP. Women using oral contraception must have started using it at least 2 months prior to screening. Women are not considered to be of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms). Or have had a surgical bilateral oophorectomy (with or without hysterectomy) or bilateral tubal ligation at least six weeks before the screening visit. In case of oophorectomy alone, the reproductive status of the woman should have been confirmed by follow up hormone level assessment.
14.Severe comorbidity (e.g., drug addiction, psychosis, diabetes)
15.Experimental agents must have been discontinued at least 8 weeks prior to screening for a period equivalent to 5 half-lives of the agent (whichever is longer)
16.Any diagnosed nasal conditions including abnormal nasal anatomy, nasal symptoms (i.e. blocked nose, nasal polyps etc.), or having product sprayed in to the nasal cavity prior to drug administration
17.Subject with concurrent disease consider
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To determine whether treatment with naloxone hydrochloride nasal spray reduces gambling urge symptoms in patients with gambling disorder.;<br> Secondary Objective: To determine the effects of naloxone hydrochloride nasal spray on gambling severity, frequency and time, internet use, self-efficacy, quality of life, alcohol consumption, depression.<br> To evaluate the safety of naloxone hydrochloride nasal spray in the treatment of gambling disorder.<br> ;Primary end point(s): Gambling symptoms (G-SAS) from Baseline to week 12 ;Timepoint(s) of evaluation of this end point: Weekly, from baseline to week 12,
- Secondary Outcome Measures
Name Time Method Timepoint(s) of evaluation of this end point: Weekly;<br> Secondary end point(s): •VAS (gambling craving) from Baseline to Week 3, 6, 9 and 12<br> •Gambling severity (PGSI) from Baseline to Week 6 and12<br> •Gambling severity (DSM-5) from Baseline to Week 6 and 12<br> •Gambling problems (NODS) from Baseline to Week 3, 6, 9 and 12<br> •Gambling expenditure and frequency from Baseline to Week 12<br> •Abstinence of gambling (GASS) from Baseline to Week 3, 6, 9 and 12<br> •Internet use (Internet disorder scale-9 short form) from Baseline to Week 6 and 12<br> •Quality of life (WHO: EUROHIS-8) from Baseline to Week 6 and 12<br> •Alcohol consumption (AUDIT) from Baseline to Week 6 and 12<br> •Depression (MADRS) from Baseline to Week 6 and 12<br> •Gambling symptoms (G-SAS) from Baseline to Week 3, 6 and 9<br>